Multiplex Molecular Diagnostics Market

As the clinical symptoms of these diseases are not pathogen specific, therefore its differential diagnosis is broad. Previously, for performing microbiologic diagnosis, one needed a combination of antigen tests, microscopy, culture, and pathogen-specific PCR assays. However, as multiplex molecular diagnostic approach came into practice, it simplified testing algorithms and laboratory workflow. Multiplex molecular diagnostics have significantly increased the diagnostic yield. Moreover, with launch of multiplex PCRs, the tests have become more sensitive than the routine culture or antigen detection. Still, there are few limitations to current multiplex molecular diagnostics test. In current form, multiplex molecular diagnostics cannot detect all potential pathogens. Besides a negative panels result doesn’t on entirely exclude infection. Further, with panel based methodology, current platforms offer few or limited options to select which organism targets needs to be tested.

Multiplex Molecular Diagnostics Market: Overview

Highly multiplexed molecular diagnostics are powerful tools for patient care, epidemiologic studies, and to control infection. It is highly likely that panel testing will be increasingly used in clinical microbiology in the future. However, multiplex molecular diagnostics assays cannot replace traditional culture based method fully. Further, additional testing for organisms needs to be included in the panel

Multiplex Molecular Diagnostics Market: Region-wise Outlook

Owing to the presence of developed economies like the U.S. and Canada, North America is anticipated to be the dominant revenue generating region for immunoaffinity columns market over the forecasting period. Many factors like well-developed high-tech diagnostic labs, presence of a large number of key players, and favorable research funding are contributing to the high revenue generation in this region. After North America, Europe is anticipated to be the second most important region for multiplex molecular diagnostics market. This is attributed to the increased number of patient care, epidemiologic studies being conducted in this region. The Asia pacific regional market for multiplex molecular diagnostics is expected to grow at the fastest rate due to factors such as rising adoption of the advanced diagnostic technologies and high prevalence of infectious diseases in the region. However, Middle-East and Africa is expected to be the least lucrative region in immunoaffinity columns market due to the lack of awareness about modern diagnostic techniques and lack of advanced clinical laboratories.

Multiplex Molecular Diagnostics Market: Key Players

Some of the key players present in global Multiplex Molecular Diagnostics market include BD, bioMérieux SA, GenMark Diagnostics, Inc, Hologic, Luminex Corporation and many more. In addition presence of small and local manufacturers across the countries will account for competiveness in multiplex molecular diagnostics market.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain

The regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
• Eastern Europe (Poland, Russia)
• Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
• Japan
• The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.